R K Pharma Inc
Samit Deb MS, RAC(US) is an experienced pharmaceutical executive currently serving as President and EVP of Manufacturing Science Technology and Global Operations at R K Pharma Inc since August 2019. Samit Deb has a comprehensive background in operations, quality assurance, and regulatory affairs, with previous leadership positions at Jubilant Pharma as VP and Head of Operations North America, and at Apicore US LLC as VP and Global Head of QC/QA & RA. With a career spanning over two decades, Samit Deb has held significant roles at Pii, Biocon, and Cipla Ltd., focusing on manufacturing operations, regulatory compliance, and quality management. Educational qualifications include an MS in Microbiology, a PG Diploma in Patent Law, and RAC certification in Regulatory Affairs.
This person is not in any teams
This person is not in any offices
R K Pharma Inc
RK Pharma Inc is a privately held US based company. We focus on the development, manufacturing, and sale of high quality and affordable generic pharmaceutical products worldwide. RK Pharma Inc has uniquely integrated development, regulatory, and manufacturing capabilities, with a focus on products with formulation challenges and first generic opportunities. Our state-of-the-art facility in Pearl River, New York specializes in managing a seamless process of bulk manufacturing through a multi-format packaging and end-product release testing suited for injectables, sterile ophthalmic and dermal products. Further product development is also being undertaken at our other locations worldwide under the supervision of our experienced formulation, analytical, quality, and regulatory leaders. Apicore LLC (www.apicore.com), a wholly owned subsidiary of RK Pharma Inc. is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry since 2003. Apicore offers a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are equipped with state-of-the-art analytical and research capabilities. RK Pharma Inc’s strong pipeline of products will be commercialized in the United States by Archis Pharma LLC (www.archispharma.com), also a wholly owned subsidiary of RK Pharma Inc